198 related articles for article (PubMed ID: 36046037)
1. Bevacizumab combined with re-irradiation in recurrent glioblastoma.
She L; Su L; Liu C
Front Oncol; 2022; 12():961014. PubMed ID: 36046037
[TBL] [Abstract][Full Text] [Related]
2. NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.
Tsien CI; Pugh SL; Dicker AP; Raizer JJ; Matuszak MM; Lallana EC; Huang J; Algan O; Deb N; Portelance L; Villano JL; Hamm JT; Oh KS; Ali AN; Kim MM; Lindhorst SM; Mehta MP
J Clin Oncol; 2023 Feb; 41(6):1285-1295. PubMed ID: 36260832
[TBL] [Abstract][Full Text] [Related]
3. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
4. Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study.
Lu G; Rao M; Zhu P; Liang B; El-Nazer RT; Fonkem E; Bhattacharjee MB; Zhu JJ
Front Neurol; 2019; 10():42. PubMed ID: 30766509
[TBL] [Abstract][Full Text] [Related]
5. Dose-dependent efficacy of bevacizumab in recurrent glioblastoma.
Melhem JM; Tahir A; Calabrese E; Granovskaya I; Atenafu EG; Sahgal A; Lim-Fat MJ; Perry JR
J Neurooncol; 2023 Feb; 161(3):633-641. PubMed ID: 36749445
[TBL] [Abstract][Full Text] [Related]
6. Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map.
Fu M; Zhou Z; Huang X; Chen Z; Zhang L; Zhang J; Hua W; Mao Y
BMC Cancer; 2023 Jun; 23(1):544. PubMed ID: 37316802
[TBL] [Abstract][Full Text] [Related]
7. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma.
Cardona AF; Rojas L; Wills B; Ruiz-Patiño A; Abril L; Hakim F; Jiménez E; Useche N; Bermúdez S; Mejía JA; Ramón JF; Carranza H; Vargas C; Otero J; Archila P; Rodríguez J; Rodríguez J; Behaine J; González D; Jacobo J; Cifuentes H; Feo O; Penagos P; Pineda D; Ricaurte L; Pino LE; Vargas C; Marquez JC; Mantilla MI; Ortiz LD; Balaña C; Rosell R; Zatarain-Barrón ZL; Arrieta O
Clin Transl Oncol; 2019 Oct; 21(10):1364-1373. PubMed ID: 30798512
[TBL] [Abstract][Full Text] [Related]
9. Re-irradiation after gross total resection of recurrent glioblastoma : Spatial pattern of recurrence and a review of the literature as a basis for target volume definition.
Straube C; Elpula G; Gempt J; Gerhardt J; Bette S; Zimmer C; Schmidt-Graf F; Meyer B; Combs SE
Strahlenther Onkol; 2017 Nov; 193(11):897-909. PubMed ID: 28616821
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W
J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
[TBL] [Abstract][Full Text] [Related]
11. Re-irradiation of recurrent IDH-wildtype glioblastoma in the bevacizumab and immunotherapy era: Target delineation, outcomes and patterns of recurrence.
Christ SM; Youssef G; Tanguturi SK; Cagney D; Shi D; McFaline-Figueroa JR; Chukwueke U; Lee EQ; Hertler C; Andratschke N; Weller M; Reardon DA; Haas-Kogan D; Guckenberger M; Wen PY; Rahman R
Clin Transl Radiat Oncol; 2024 Jan; 44():100697. PubMed ID: 38046107
[TBL] [Abstract][Full Text] [Related]
12. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
[TBL] [Abstract][Full Text] [Related]
13. The addition of chloroquine and bevacizumab to standard radiochemotherapy for recurrent glioblastoma multiforme.
Witte HM; Riecke A; Steinestel K; Schulz C; Küchler J; Gebauer N; Tronnier V; Leppert J
Br J Neurosurg; 2024 Apr; 38(2):404-410. PubMed ID: 33590799
[TBL] [Abstract][Full Text] [Related]
14. Clinical Benefit of Bevacizumab and Irinotecan (BEV+IRI) in Patients With Relapsed/Refractory Glioblastoma (r/rGBM) and its Potential Predictors.
Park JH; Lee HS; Choi JW; Lim SD; Koh HK; Cho KR; Cho J; Koh YC; Yoon SY
Anticancer Res; 2022 Dec; 42(12):6091-6098. PubMed ID: 36456153
[TBL] [Abstract][Full Text] [Related]
15. Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma.
Schnell O; Thorsteinsdottir J; Fleischmann DF; Lenski M; Abenhardt W; Giese A; Tonn JC; Belka C; Kreth FW; Niyazi M
J Neurooncol; 2016 Dec; 130(3):591-599. PubMed ID: 27599828
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
Herrlinger U; Schäfer N; Steinbach JP; Weyerbrock A; Hau P; Goldbrunner R; Friedrich F; Rohde V; Ringel F; Schlegel U; Sabel M; Ronellenfitsch MW; Uhl M; Maciaczyk J; Grau S; Schnell O; Hänel M; Krex D; Vajkoczy P; Gerlach R; Kortmann RD; Mehdorn M; Tüttenberg J; Mayer-Steinacker R; Fietkau R; Brehmer S; Mack F; Stuplich M; Kebir S; Kohnen R; Dunkl E; Leutgeb B; Proescholdt M; Pietsch T; Urbach H; Belka C; Stummer W; Glas M
J Clin Oncol; 2016 May; 34(14):1611-9. PubMed ID: 26976423
[TBL] [Abstract][Full Text] [Related]
17. Outcome of Second Line Treatment of Recurrent High- Grade Glioma by re-Irradiation or Bevacizumab-based Chemotherapy: A Cross Sectional Study.
Anvari K; Shahabadi M; Welsh JS; Javadinia SA; Zarei E
Asian Pac J Cancer Prev; 2023 May; 24(5):1507-1511. PubMed ID: 37247269
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Bevacizumab Combined with Other Therapeutic Regimens for Treatment of Recurrent Glioblastoma: A Network Meta-analysis.
Dongpo S; Zhengyao Z; Xiaozhuo L; Qing W; Mingming F; Fengqun M; Mei L; Qian H; Tong C
World Neurosurg; 2022 Apr; 160():e61-e79. PubMed ID: 34973444
[TBL] [Abstract][Full Text] [Related]
19. A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
Brandes AA; Gil-Gil M; Saran F; Carpentier AF; Nowak AK; Mason W; Zagonel V; Dubois F; Finocchiaro G; Fountzilas G; Cernea DM; Chinot O; Anghel R; Ghiringhelli F; Beauchesne P; Lombardi G; Franceschi E; Makrutzki M; Mpofu C; Urban HJ; Pichler J
Oncologist; 2019 Apr; 24(4):521-528. PubMed ID: 30266892
[TBL] [Abstract][Full Text] [Related]
20. The prognosis for patients with newly diagnosed glioblastoma receiving bevacizumab combination therapy: a meta-analysis.
Liao KL; Huang S; Wu YP
Onco Targets Ther; 2018; 11():3513-3520. PubMed ID: 29950856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
